Lexicon PharmaceuticalsLXRX
LXRX
About: Lexicon Pharmaceuticals Inc is a biopharmaceutical company. It is engaged in the discovery, development, and commercialization of pharmaceutical products for the treatment of human diseases. Some of its drug candidates are LX9211, an orally-delivered small molecule drug candidate, also developing LX9851, an orally-delivered small molecule drug candidate, as a treatment for obesity and associated cardiometabolic.
Employees: 103
0
Funds holding %
of 7,338 funds
–
Analysts bullish %
Fund manager confidence
Based on 2025 Q1 regulatory disclosures by fund managers ($100M+ AUM)
588% more call options, than puts
Call options by funds: $358K | Put options by funds: $52K
10% more first-time investments, than exits
New positions opened: 32 | Existing positions closed: 29
6% more repeat investments, than reductions
Existing positions increased: 34 | Existing positions reduced: 32
1% more funds holding
Funds holding: 126 [Q4 2024] → 127 (+1) [Q1 2025]
0% more funds holding in top 10
Funds holding in top 10: 1 [Q4 2024] → 1 (+0) [Q1 2025]
8.81% less ownership
Funds ownership: 82.34% [Q4 2024] → 73.53% (-8.81%) [Q1 2025]
44% less capital invested
Capital invested by funds: $220M [Q4 2024] → $122M (-$97.6M) [Q1 2025]
Research analyst outlook
2 Wall Street Analysts provided 1 year price targets over the past 3 months
Low target
$1.90
71%
upside
Avg. target
$2.95
166%
upside
High target
$4
260%
upside
2 analyst ratings
2 positive
100%
0 neutral
0%
0 negative
0%
Citigroup Yigal Nochomovitz | 71%upside $1.90 | Buy Maintained | 7 Aug 2025 |
HC Wainwright & Co. Joseph Pantginis | 260%upside $4 | Buy Reiterated | 24 Jun 2025 |
Financial journalist opinion
Based on 8 articles about LXRX published over the past 30 days
Positive
Zacks Investment Research
5 days ago
Lexicon (LXRX) Upgraded to Buy: Here's What You Should Know
Lexicon (LXRX) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.
Positive
The Motley Fool
1 week ago
Lexicon (LXRX) Q2 Revenue Soars 1,706%
Lexicon (LXRX) Q2 Revenue Soars 1,706%
Neutral
Seeking Alpha
1 week ago
Lexicon Pharmaceuticals, Inc. (LXRX) Q2 2025 Earnings Call Transcript
Lexicon Pharmaceuticals, Inc. (NASDAQ:LXRX ) Q2 2025 Earnings Conference Call August 6, 2025 8:30 AM ET Company Participants Craig B. Granowitz - Senior VP & Chief Medical Officer Lisa M.
Positive
Zacks Investment Research
1 week ago
Lexicon Pharmaceuticals (LXRX) Q2 Earnings and Revenues Top Estimates
Lexicon Pharmaceuticals (LXRX) came out with quarterly earnings of $0.01 per share, beating the Zacks Consensus Estimate of a loss of $0.08 per share. This compares to a loss of $0.17 per share a year ago.
Neutral
GlobeNewsWire
1 week ago
Lexicon Pharmaceuticals Reports Second Quarter 2025 Financial Results and Provides Business Updates
Partnership discussions for pilavapadin remain underway following Phase 2b PROGRESS study results IND-enabling studies of LX9851 for obesity and related disorders on track for completion in 2025 with licensee Novo Nordisk expected to submit IND Enrollment completion for SONATA Phase 3 study in both obstructive and non-obstructive hypertrophic cardiomyopathy (HCM) on target for 2026 Conference call and webcast at 8:30 am ET THE WOODLANDS, Texas, Aug. 06, 2025 (GLOBE NEWSWIRE) -- Lexicon Pharmaceuticals, Inc. (Nasdaq: LXRX), today reported financial results for the three months ended June 30, 2025, and provided an update on key corporate milestones and accomplishments. “We continue to make great strides against the strategy we set forth as an R&D focused company,” said Mike Exton, Ph.D.
Neutral
GlobeNewsWire
1 week ago
Lexicon Pharmaceuticals Regains Compliance with Nasdaq Minimum Bid Price Requirement
THE WOODLANDS, Texas, July 31, 2025 (GLOBE NEWSWIRE) -- Lexicon Pharmaceuticals, Inc. (Nasdaq: LXRX) today announced that Nasdaq's listing qualifications staff has determined that the closing bid price of the Company's common stock has been at $1.00 per share or greater for ten consecutive business days and that, accordingly, the Company has regained compliance with Nasdaq Listing Rule 5550(a)(2). This update was previously disclosed in the Company's Current Report on Form 8-K filed on July 28, 2025.
Neutral
GlobeNewsWire
3 weeks ago
Lexicon Pharmaceuticals to Report Second Quarter 2025 Financial Results on August 6, 2025
THE WOODLANDS, Texas, July 23, 2025 (GLOBE NEWSWIRE) -- Lexicon Pharmaceuticals, Inc. (Nasdaq: LXRX) today announced the Company will release its second quarter 2025 financial results on Wednesday, August 6, 2025, prior to market open. Management will conduct a conference call and live webcast at 8:30 a.m. ET (7:30 a.m. CT) that day to discuss the financial results and to provide a business update.
Neutral
GlobeNewsWire
3 weeks ago
Lexicon to Present Patient-reported Data on Diabetic Peripheral Neuropathic Pain (DPNP) at the 7th Annual Meeting of the American Society of Pain and Neuroscience (ASPN 2025)
Patient insights informed the development of pilavapadin, Lexicon's investigational, novel, non-opioid treatment for people suffering from DPNP Patient insights informed the development of pilavapadin, Lexicon's investigational, novel, non-opioid treatment for people suffering from DPNP
Neutral
GlobeNewsWire
1 month ago
Data Demonstrating Sotagliflozin Reduces the Risk of Clinically Important Hypoglycemic Events in Adults with Type 1 Diabetes When Added to Insulin Presented at the 85th Scientific Sessions of the American Diabetes Association (ADA)
Oral presentation highlighted the post-hoc analysis during the “Interventions to Prevent Hypoglycemia: Bench to Bedside” session Treatment with sotagliflozin resulted in no increased risk and a reduction in hypoglycemia events, particularly in patients with blood glucose ≤55 mg/dL THE WOODLANDS, Texas, June 23, 2025 (GLOBE NEWSWIRE) -- Lexicon Pharmaceuticals, Inc. (Nasdaq: LXRX) announced that a post-hoc analysis of clinical study data showing a reduction in hypoglycemic events when sotagliflozin was added to optimized insulin therapy for people with type 1 diabetes (T1D) was presented yesterday during the 85th Scientific Sessions of the American Diabetes Association (ADA) in Chicago, Illinois. The ADA emphasizes that hypoglycemia remains an important patient management issue in T1D.
Neutral
GlobeNewsWire
1 month ago
Lexicon to Present Data at the 85th Scientific Sessions of the American Diabetes Association (ADA)
THE WOODLANDS, Texas, June 18, 2025 (GLOBE NEWSWIRE) -- Lexicon Pharmaceuticals, Inc. (Nasdaq: LXRX) today announced that data from a study evaluating the impact of sotagliflozin on hypoglycemia in people with type 1 diabetes will be delivered as an oral presentation on Sunday, June 22, during the 85th Scientific Sessions of the American Diabetes Association (ADA). At the meeting, the company will also present topline data from its PROGRESS Phase 2b study evaluating pilavapadin (LX9211) in adults with diabetic peripheral neuropathic pain.
Charts implemented using Lightweight Charts™